CheckMate 77T Trial: Nivolumab in Lung Cancer

checkmate 77t trial

CheckMate 77T
Perioperative Nivolumab in Resectable Lung Cancer

Design:

  • A phase 3, randomized, placebo-controlled, double-blind trial

Objective:

  • To assess the effect of perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) with nivolumab on improving outcomes in patients with resectable non-small-cell lung cancer (NSCLC).

Patients:

  • 461 patients

Inclusion criteria:

  • Age 19-80 years
  • Implantation of BP-SES for ACS

Exclusion criteria:

  • Increased bleeding risk (e.g., prior intracranial hemorrhage, Hb<8 g/dL, platelets <100,000/mL)
  • Need for oral anticoagulation
  • Current or anticipated pregnancy
  • Life expectancy <1 year

Comparison:

  • Perioperative Nivolumab + Chemotherapy (n = 229)
  • Versus
  • Perioperative Placebo + Chemotherapy (n = 232)

Primary Outcome:

  1. Event-free survival %
  • Nivolumab: 70.2%
  • Placebo: 50.0%
  • HR: 0.58, 97.36% CI: 0.42 to 0.81 (P < 0.001)

Secondary Outcomes:

  1. Pathological complete response %
  • Nivolumab: 25.3%
  • Placebo: 4.7%
  • OR: 6.64, 95% CI: 3.40 to 12.97
  1. Major pathological response %
  • Nivolumab: 35.4%
  • Placebo: 12.1%
  • OR: 4.01, 95% CI: 2.48 to 6.49

Conclusion:

  • In adults with resectable stage IIA to IIIB NSCLC, perioperative nivolumab significantly improved event-free survival at 18 months compared to chemotherapy alone.

Reference:


This data highlights the key points of the CheckMate 77T trial, comparing the outcomes of perioperative nivolumab combined with chemotherapy versus chemotherapy alone in patients with resectable non-small-cell lung cancer.

Comments are closed.